Skip to main content

Table 1 Patient demographics, personal circumstances, clinical characteristics, and current treatment

From: Real-world assessment of the impact of “OFF” episodes on health-related quality of life among patients with Parkinson’s disease in the United States

  Overall
(N = 722)
No “OFF” episodes
(n = 401)
“OFF”
episodes
(n = 321)
P value
Age, ya
N 722 401 321 0.253b
 Mean (SD) 67.3 (11.6) 67.7 (10.5) 66.7 (12.7)
 Min, max 26, 90 26, 90 37, 90
Sex
N 722 401 321 0.202c
 Male 447 (61.9) 240 (59.9) 207 (64.5)
 Female 275 (38.1) 161 (40.1) 114 (35.5)
Employment status
N 711 394 317 0.008c
 Works full-time 118 (16.6) 78 (19.8) 40 (12.6)
 Works part-time 90 (12.7) 38 (9.6) 52 (16.4)
 Long-term sick leave 4 (0.6) 2 (0.5) 2 (0.6)
 Homemaker 64 (9.0) 42 (10.7) 22 (6.9)
 Student 1 (0.1) 1 (0.3) 0
 Retired 410 (57.7) 221 (56.1) 189 (59.6)
 Unemployed 24 (3.4) 12 (3.0) 12 (3.8)
Long-term sick leave/retired/unemployed due to PD
N 387 212 175 <  0.001c
 Yes 70 (18.1) 27 (12.7) 43 (24.6)
 No 317 (81.9) 185 (87.3) 132 (75.4)
Living situation
N 708 394 314 0.001c
 Alone 63 (8.9) 46 (11.7) 17 (5.4)
 With spouse/partner 568 (80.2) 318 (80.7) 250 (79.6)
 With other family 58 (8.2) 22 (5.6) 36 (11.5)
 With friends 1 (0.1) 1 (0.3) 0
 Long-term care facility 14 (2.0) 5 (1.3) 9 (2.9)
 Sheltered housing 1 (0.1) 1 (0.3) 0
 Other 3 (0.4) 1 (0.3) 2 (0.6)
Current Hoehn and Yahr score
N 722 401 321 <  0.001c
 1 59 (8.2) 54 (13.5) 5 (1.6)
 1.5 87 (12.0) 73 (18.2) 14 (4.4)
 2 101 (14.0) 73 (18.2) 28 (8.7)
 2.5 152 (21.1) 74 (18.5) 78 (24.3)
 3 231 (32.0) 104 (25.9) 127 (39.6)
 4 83 (11.5) 21 (5.2) 62 (19.3)
 5 9 (1.2) 2 (0.5) 7 (2.2)
Age at PD diagnosis, y
N 555 319 236 <  0.001b
 Mean (SD) 61.2 (11.4) 62.9 (10.4) 58.9 (12.3)
 Min, max 24.6, 88.0 24.6, 88.0 29.8, 84.3
Time since PD diagnosis, y
N 555 319 236 <  0.001b
 Mean (SD) 4.5 (3.6) 3.6 (3.1) 5.9 (3.9)
 Min, max 0.0, 20.9 0.0, 17.6 0.0, 20.9
Current prescribed treatment classes
N 722 401 321  
 Carbidopa/levodopa 722 (100.0) 401 (100.0) 321 (100.0) 1.000c
 COMT inhibitor 119 (16.5) 48 (12.0) 71 (22.1) <  0.001c
 Dopamine agonist 177 (24.5) 73 (18.2) 104 (32.4) <  0.001c
 MAO-B inhibitor 118 (16.3) 50 (12.5) 68 (21.2) 0.002c
 NMDA receptor antagonist 90 (12.5) 24 (6.0) 66 (20.6) <  0.001c
 Device-aided treatment 37 (5.1) 11 (2.7) 26 (8.1) 0.001c
 Other 20 (2.8) 7 (1.7) 13 (4.0) 0.061c
Number of prescribed treatment classes
N 722 401 321  
 Mean (SD) 1.8 (0.9) 1.5 (0.7) 2.1 (1.1) <  0.001b
 Min, Max 1.0, 7.0 1.0, 4.0 1.0, 7.0  
Levodopa equivalent daily dose
N 698 385 313 <  0.001c
 1–499 mg 468 (67.0) 282 (73.2) 186 (59.4)
 500–999 mg 187 (26.8) 84 (21.8) 103 (32.9)
 1000+ mg 43 (6.2) 19 (4.9) 24 (7.7)
  1. Data are reported as n (%) unless specified otherwise
  2. aPatients reported to be aged ≥90 years of age were assumed to be 90 years of age in this analysis. bP values were calculated by t-tests. cP values were calculated by Fisher’s exact/χ2 tests
  3. COMT catechol-O-methyl transferase; MAOB monoamine oxidase type B; NMDA N-methyl-D-aspartate; PD Parkinson’s disease; SD standard deviation